The drug received accelerated approval in October 2017 as monotherapy for adults with MCL who have received at least one ...

AZN's key medicines, mainly cancer drugs, Lynparza, Tagrisso and Imfinzi, and diabetes medicine Farxiga are expected to have driven the company's top line.

Jennifer A. Woyach, MD, has been named the new director of the division of hematology at The Ohio State University ...

AstraZeneca PLC (LON:AZN), a leading global biopharmaceutical company with a market capitalization of $216.74 billion, has been making significant strides in the pharmaceutical industry, particularly ...

Flagship Harbor Advisors LLC lowered its holdings in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 2.5% during the 4th ...

AstraZeneca's Calquence has hit the mark in the phase 3 AMPLIFY trial in chronic lymphocytic leukaemia (CLL), a study that chief executive Pascal Soriot recently said could be a "blockbuster ...

Through the issuance of Inauguration Day executive orders, the Trump Administration signaled its apparent intent to tackle ...

As the next round of Medicare drug pricing negotiations get underway, experts predict President Trump may seek to weaken the program.

J&J JNJ announced fourth-quarter and full-year 2024 results, starting the earnings season for the drug and biotech sector.

WILMINGTON, Del., January 17, 2025--AstraZeneca’s CALQUENCE® (acalabrutinib) in combination with bendamustine and rituximab has been approved in the US for the treatment of adult patients with ...

Medicare will soon negotiate prices for 15 more drugs as part of an effort to reduce costs for older adults and people with disabilities.